BIONTECH: iNeST update marks platform potential in the early lines of treatment | BUY | USD50 vs. 45
BIONTECH - BUY | USD50 vs. 45iNeST update marks platform potential in the early lines of treatment
BNT122 shows manageable safety in heavily pre-treated patients
BNT122 elicits neoantigen-specific response in multiple tumours
While not abundant, BNT122 data showed clinical responses in hard-to-treat patients
Looking ahead of the ongoing clinical studies of BNT122
Increase in FV following the addition of adjuvant CRC
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.